The biggest risk for pre-commercial companies is being singularly focused on a lean development program without planning for the additional data needed to support favorable pricing, clinical practice, and long-term market success. Early investment in medical affairs expertise is essential. Even a single FTE or experienced medical affairs consultant pays significant dividends later.

Some people need to “think out loud.” Others are eager to get right to the point. Toss in challenging schedules and countless communication platforms at our fingertips — a reality amplified by today's hybrid and virtual work environments — and the decision doesn’t get any easier. And, of course, this is unlikely to get better as more “content” is created in seconds due to the proliferation of AI.

The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural piece, 12 authors from our team have contributed their insight, experience, and perspective on the biopharma industry.